Tetrahyrobiopterin (BH4) is a required cofactor for the synthesis of nitric oxide by endothelial nitric oxide synthase (eNOS) and BH4 bioavailability within the endothelium is a critical factor in regulating the balance between NO and superoxide production by eNOS (eNOS coupling). BH4 levels are determined by the activity of GTP cyclohydrolase I (GTPCH), the rate-limiting enzyme in de novo BH4 biosynthesis. However, BH4 levels may also be influenced by oxidation, forming 7,8-dihydrobiopterin (BH2), that promotes eNOS uncoupling. Conversely, dihydrofolate reductase (DHFR) can regenerate BH4 from BH2, but the functional importance of DHFR in maintaining eNOS coupling remains unclear. We investigated the role of DHFR in regulating BH4 vs. BH2 levels in endothelial cells and in cell lines expressing eNOS combined with tetregulated GTPCH expression, in order to compare the effects of low or high levels of de novo BH4 biosynthesis. Pharmacological inhibition of DHFR activity by MTX, or genetic knockdown of DHFR protein by RNA interference, reduced intracellular BH4 and increased BH2 levels resulting in enzymatic uncoupling of eNOS, as indicated by increased eNOS-dependent superoxide but reduced NO production. In contrast to the decreased BH4:BH2 ratio induced by DHFR knockdown, GTPCH knockdown greatly reduced total biopterin levels, but with no change in BH4:BH2 ratio. In cells expressing eNOS with low biopterin levels, DHFR inhibition or knockdown further diminished the BH4:BH2 ratio and exacerbated eNOS uncoupling. Taken together, these data reveal a key role for DHFR in eNOS coupling, by maintaining BH4:BH2 ratio, particularly in conditions of low total biopterin availability.
SUMMARY
Tetrahyrobiopterin (BH4) is a required cofactor for the synthesis of nitric oxide by endothelial nitric oxide synthase (eNOS) and BH4 bioavailability within the endothelium is a critical factor in regulating the balance between NO and superoxide production by eNOS (eNOS coupling). BH4 levels are determined by the activity of GTP cyclohydrolase I (GTPCH), the rate-limiting enzyme in de novo BH4 biosynthesis. However, BH4 levels may also be influenced by oxidation, forming 7,8-dihydrobiopterin (BH2), that promotes eNOS uncoupling. Conversely, dihydrofolate reductase (DHFR) can regenerate BH4 from BH2, but the functional importance of DHFR in maintaining eNOS coupling remains unclear. We investigated the role of DHFR in regulating BH4 vs. BH2 levels in endothelial cells and in cell lines expressing eNOS combined with tetregulated GTPCH expression, in order to compare the effects of low or high levels of de novo BH4 biosynthesis. Pharmacological inhibition of DHFR activity by MTX, or genetic knockdown of DHFR protein by RNA interference, reduced intracellular BH4 and increased BH2 levels resulting in enzymatic uncoupling of eNOS, as indicated by increased eNOS-dependent superoxide but reduced NO production. In contrast to the decreased BH4:BH2 ratio induced by DHFR knockdown, GTPCH knockdown greatly reduced total biopterin levels, but with no change in BH4:BH2 ratio. In cells expressing eNOS with low biopterin levels, DHFR inhibition or knockdown further diminished the BH4:BH2 ratio and exacerbated eNOS uncoupling. Taken together, these data reveal a key role for DHFR in eNOS coupling, by maintaining BH4:BH2 ratio, particularly in conditions of low total biopterin availability.
INTRODUCTION
In vascular disease states such as atherosclerosis and diabetes, endothelial nitric oxide (NO) bioactivity is reduced and oxidative stress is increased, resulting in endothelial dysfunction. It has become apparent that enzymatic "coupling" of endothelial NO synthase by its cofactor tetrahydrobiopterin (BH4) plays a key role in maintaining endothelial function. Indeed, the balance between NO and superoxide production by eNOS appears to be determined by the availability of BH4, versus the abundance of 7,8-dihydrobiopterin (BH2), that is inactive for NOS cofactor function and may compete with BH4 for NOS binding (1) . Intracellular biopterin levels are regulated principally by the activity of the de novo biosynthetic pathway ( Figure 1 ). Guanosine triphosphate cyclohydrolase I (GTPCH; E.C. 3.5.4.16) catalyzes the formation of dihydroneopterin triphosphate from GTP, and BH4 is generated by two further steps through 6-pyruvoyltetrahydropterin synthase and sepiapterin reductase. GTPCH appears to be the rate-limiting enzyme in BH4 biosynthesis, and overexpression of GTPCH is sufficient to augment BH4 levels in cultured endothelial cells (2) .
Electron paramagnetic resonance spectroscopy studies have shown that BH4 both stabilizes and donates electrons to the ferrousdioxygen complex in the oxygenase domain, as the initiating step of L-arginine oxidation (3) (4) (5) . In this reaction BH4 forms the protonated trihydrobiopterin cation radical, which is subsequently reduced by electron transfer from NOS flavins. When BH4 availability is limiting, electron transfer from NOS flavins becomes uncoupled from L-arginine oxidation, eNOS generates superoxide rather than NO, BH4 becomes oxidized to catalytically incompetent BH2, and a futile feed-forward cascade of BH4 destruction proceeds (1) . Recent studies reveal that BH4 and BH2 bind eNOS with equal affinity and that BH2 can efficiently replace eNOS-bound BH4, resulting in eNOS uncoupling (6) . Indeed, we have previously shown that the relative abundance of eNOS vs. BH4, together with the intracellular BH4:BH2 ratio, rather than absolute concentrations of BH4, are the key determinants of eNOS uncoupling (7), a hypothesis supported by a recent publication where BH2 levels are elevated following exposure of bovine aortic endothelial cells to DHFR-specific siRNA (8) . Thus, mechanisms that regulate BH4:BH2 ratio, independently of overall biopterin levels, may play an equally important role in regulating eNOS coupling as the well-establihsed role of GTCPH, that regulates de novo BH4 biosynthesis. In addition to key roles in folate metabolism, dihydrofolate reductase (DHFR; E.C. 1.5.1.3) can reduce BH2, thus regenerating BH4 (9, 10) . It is therefore likely that net BH4 bioavailability within the endothelium reflects the balance between de novo BH4 synthesis, loss of BH4 by oxidation to BH2, and the regeneration of BH4 by DHFR. In human liver extracts, DHFR has been shown to reduce BH2 back to BH4 as part of the salvage pathway for biopterin synthesis (11) . However, the role of this pathway and the extent to which it regulates intracellular BH4 levels in vivo remains unknown. Recent work by Chalupsky and Cai investigated the functionality of endothelial DHFR in cultured bovine aortic endothelial cells (2) . Exposure to angiotensin II, down-regulated DHFR expression, decreased BH4 levels, and increased eNOS uncoupling, that was restored by overexpression of DHFR (2) . A recent study also suggests that perturbation of BH4 metabolism differentially affects eNOS phosphorylation sites. Knockdown of DHFR by siRNA inhibits VEGF-induced dephosphorylation of eNOS at Ser-116, an effect that is completely recovered by addition of exogenous BH4 (8) . However, the requirement for DHFR in regulating intracellular BH4 homeostasis, and the quantitative relationships that relate BH4 de novo synthesis vs. BH4 recycling to eNOS coupling remain uncertain. Accordingly, we sought to address these questions using both pharmacologic and genetic manipulation of DHFR activity, and related these interventions to effects on eNOS coupling. We manipulated DHFR in both endothelial cells and in novel cell lines that stably express an eNOS-GFP fusion protein, and where expression of human GTPCH can be regulated by doxycyline, in order to test the effects of variations in intracellular BH4 biosynthesis (7) . We report that while GTPCH is the key regulator of the total amount of intracellular biopterins, DHFR is critical to eNOS function by determining BH4:BH2 ratio and thus in maintaining eNOS coupling. In particular, DHFR is important in preventing "selfpropagated" eNOS uncoupling in conditions of low total biopterin levels, when eNOSdependent oxidation of BH4 that would further exacerbate eNOS uncoupling, can be rescued by DHFR.
3 responsive element. Individual colonies were isolated, analyzed for GTPCH expression and a cell line, termed "GCH cells", was established from expansion of a single colony. GCH/eNOS cells were produced by stable transfection of GCH cells with a plasmid encoding a human eNOS-eGFP fusion protein, as described (13) . All cell lines underwent at least three rounds of clonal selection.
Cell culture sEnd.1 murine endothelial cells were cultured in Dulbecco"s Modified Eagle Medium (DMEM, Gibco Life Technologies, MD) supplemented with glutamine (2 mM), penicillin (100 U/ml), and streptomycin (0.1 mg/ml). Additionally, GCH cells were maintained using media containing the antibiotics hygromycin (200 µg/ml) and genetecin (200 µg/ml), while eNOS/eGFP cell media also included puromycin (2 µg/ml). Where appropriate, doxycycline (1 µg/ml) was added to cell culture media to abolish transcription of GCH1 mRNA.
Biopterin quantification by HPLC with electrochemical detection BH4, BH2 and biopterin (B) levels in cell lysates were determined by HPLC followed by electrochemical and fluorescent detection, as previously described (14) . Briefly, cells were grown to confluence and harvested by trypsinization. Cell pellets were resuspended in phosphate buffered saline (50 mM), pH 7.4, containing dithioerythritol (1 mM) and EDTA (100 µM) and subjected to three free-thaw cycles. Following centrifugation (15 min at 13,000 rpm and 4 o C), samples were transferred to new, cooled micro tubes and precipitated with cold phosphoric acid (1 M), trichloroacetic acid (TCA; 2 M) and DTE (1 mM). Samples were vigorously mixed and then centrifuged for 15 min at 13,000 rpm and 4°C. Samples were injected onto an isocratic HPLC system and quantified using sequential electrochemical (Coulochem III, ESA Inc., UK) and fluorescence (Jasco, UK) detection. HPLC separation was performed using a 250 mm, ACE C-18 column (Hichrom, UK) and mobile phase comprising of sodium acetate (50 mM), citric acid (5 mM), EDTA (48 µM), and DTE (160 µM) (pH=5.2) (all ultrapure electrochemical HPLC grade) at a flow rate of 1.3 ml/min. Background currents of +500 µA and -50 µA were used for the detection of BH4 on electrochemical cells E1 and E2, respectively. 7,8-BH2 and biopterin were measured using a Jasco FP2020 fluorescence detector. Quantification of BH4, BH2 and B was done by comparison with authentic external standards and normalized to sample protein content. 
Western blotting

Measurement of eNOS protein levels by eGFP fluorescence
Cell pellets were lysed in phosphate-buffered saline containing dithioerythritol (1 mM) and EDTA (100 µM) as for BH4 analysis. Sample fluorescence was quantified using a TEKAN fluorescence plate reader and a standard curve generated using recombinant eGFP. Because recombinant eNOS was expressed as an eNOSeGFP fusion protein, eGFP fluorescence and eNOS levels were directly proportional. Importantly, determination of both eGFP fluorescence and BH4 levels was done on identical cell samples, allowing accurate determination of the BH4:eNOS ratio.
washed three times in PBS and incubated in Krebs-Hepes buffer in the presence or absence of L-NAME (100 µM). After one hour, dihydroethidium (25 µM) was added and cells were then incubated for an additional 20 minutes at 37 o C. Cells were then harvested by scraping, centrifuged, and lysed in ice-cold methanol. Hydrochloric acid (100 mM) was added (1:1 v/v) prior to loading into the autosampler for analysis. All samples were stored in darkened tubes and protected from light at all times. Separation of dihydroethidium, 2-hydroxyethidium and ethidium was performed using a gradient HPLC system (Jasco, UK) with an ODS3 reverse phase column (250 mm, 4.5 mm; Hichrom, UK), and quantified using a fluorescence detector set at 510 nm (excitation) and 595 nm (emission). A linear gradient was applied from Mobile phase A (0.1% TFA) to Mobile phase B (0.085% TFA in acetonitrile) over 23 minutes (30% acetonitrile to 50% acetonitrile).
Analysis of NO synthesis by eNOS
Cellular NO synthesis by eNOS was assessed by measuring the conversion of 14 C L-arginine to citrulline with HPLC detection, in the presence and absence of L-NMMA, as previously described (17) . DHFR and GCH knockdown by RNA interference DHFR and GCH-specific, "ON-TARGETplus SMARTpool" siRNA was purchased from Dharmacon Thermo Scientific. The siRNAs were used as a pool of four specific siRNA duplexes with the following sequences:
sEnd.1 endothelial cells were grown in Dulbecco"s Modified Eagle Medium (DMEM, Gibco Life Technologies, MD) supplemented with glutamine (2 mM), penicillin (100 U/ml), and streptomycin (0.1 mg/ml). 24 h prior to transfection, cells were seeded into 6 well plates. Cells were then transfected with GCH-or DHFR-specific siRNA (100 nM), GAPDH positive (100 nM) or nonspecific pooled duplex negative control siRNA (100 nM). Cells were cultured for 72 hours and gene silencing was detected by analysis of DHFR and GTPCH protein expression by Western blotting using DHFR and GTPCH-specific antibodies.
Measurement of cellular antioxidant capacity
Cellular antioxidant status was assessed using an antioxidant detection kit that quantifies the combined antioxidant capacity of aqueous and lipid-soluble antioxidant including vitamins, proteins, lipids, glutathione, uric acid. Cells were harvested into assay buffer (50 mM phosphate buffered saline, pH 7.4, containing dithioerythritol (1 mM) and EDTA (100 µM) and subjected to three free-thaw cycles). Protocol was then followed as per manufacturer"s instructions.
Statistical analysis
Data are presented as mean + SEM. Data were subjected to the Kolmogorov-Smirnov test to determine distribution. Groups were compared using the Mann-Whitney U test for nonparametric data or the Students t-test for parametric data.
When comparing multiple groups data were analyzed by analysis of variance (ANOVA) with Newman-Keuls post test for parametric data or Kruskal-Wallis test with Dunns post test for non-parametric data. Correlation testing was performed using the Pearson test. A value of P<0.05 was considered statistically significant.
RESULTS
Effects of DHFR overexpression in endothelial cells
We first investigated the effect of DHFR overexpression on biopterin levels and eNOS regulation in sEnd.1 murine endothelial cells. DHFR protein was increased 5-fold following transfection of sEnd.1 endothelial cells with DHFR cDNA, compared with untreated, GFP or mock transfection controls ( Figure 2A ). However, DHFR overexpression did not change the intracellular levels of either BH4 or total biopterins ( Figure 2B and C). Similarly, neither endothelial-derived NO nor superoxide production were altered by DHFR overexpression, as evidenced by conversion of radiolabeled arginine to citrulline and by 2-hydroxyethidium accumulation, respectively ( Figure 2D and E). These observations suggest that sEnd.1 endothelial cells contain sufficient DHFR to regulate steady-state BH4 levels and efficiently couple eNOS, such that overexpression of DHFR has no further effects.
Effects of DHFR inhibition by methotrexate (MTX) in endothelial cells
We next sought to evaluate the effects of DHFR inhibition, using MTX, on steady-state biopterin levels, in order to determine the requirement of DHFR for maintenance of BH4 homeostasis and eNOS coupling. We compared BH4, BH2 and biopterin levels in sEnd.1 endothelial cells following exposure to MTX (1 µM) for 16 hours. Western blot analysis revealed that MTX did not alter protein levels of eNOS, DHFR, GCH or GAPDH ( Figure 3A) . However, intracellular BH4 levels were significantly decreased by exposure to MTX (from 308.0 ± 40.5 to 229.0 ± 36.3 pmol/mg protein)( Figure  3B , P<0.05), while the levels of BH2 and B were markedly elevated ( Figure 3C and D, P<0.001). Total biopterin levels (BH4 + BH2 + B) were unaltered by MTX, but there was a striking decrease in the ratio of reduced to oxidized biopterins (BH4:BH2 and B) (13.8 ± 2.3 vs. 3.3 ± 0.2; Figure 3E and F, P<0.001). Furthermore, MTX induced eNOS uncoupling, demonstrated by the simultaneous decrease in NO synthesis (P<0.05; Figure 4A ) and elevation in eNOS-dependent superoxide production (P<0.01; Figure 4B and C). Additional effects of MTX treatment on superoxide dismutase (SOD) protein levels and general cellular antioxidant capacity may explain changes in 2-hydroxyethidium accumulation observed in the presence of MTX. To eliminate these potentially confounding effects, we quantified CuZn-, Mnand EC SOD protein levels using Western blotting. No effect of MTX was observed on SOD levels (Supplementary Figure 1) . However, a significant reduction in cellular antioxidant capacity was detected following incubation of sEnd.1 endothelial cells, GCH and GCH/eNOS cells with MTX (*P<0.05, Supplementary  Figure 2) . No confounding effects of DHFR inhibition on cell growth and viability were observed (data not shown).
Effects of DHFR or GCH knockdown by RNA interference
We next investigated the effects of reduced DHFR expression, by siRNA, rather than pharmacologic DHFR inhibition, and sought to compare with the effects of reduced GTPCH expression, in order to determine the functional relationships between BH4 biosythesis andBH4 recycling for eNOS coupling. Following exposure of sEnd.1 endothelial cells to DHFRor GTPCH-targeted siRNA for 72 h, DHFR or GTCPH protein was reduced by approximately 95% or 90%, respectively. No non-specific effects of control GAPDH-targeted siRNA, nontargeted scrambled control siRNA, or transfection reagent alone (mock) were observed by Western blotting ( Figure 5A ). Cells treated with DHFR, GTPCH and control siRNA were simultaneously prepared for biopterin analysis. As observed with DHFR inhibition using MTX, knockdown of DHFR resulted in a 40% decrease in intracellular BH4 ( Figure 5B ) and a 2-fold elevation in BH2 levels ( Figure 5C ), while total biopterins remained unchanged ( Figure 5D ). In contrast, knockdown of GTPCH reduced BH4 and BH2, as well as total biopterin levels, by >90%. Consequently, a striking reduction in the BH4:BH2 ratio was observed in the presence of DHFR knockdown, but not GTPCH knockdown (4.8 ± 1.5 to 1.9 ± 0.8) (P<0.05, Figure 5E ). eNOS uncoupling, evidenced by increased total and eNOS-dependent superoxide (P<0.05, Figure 5G and 5H), as well as a reduced conversion of arginine to citrulline, was significantly increased in the presence of both DHFR-and GCH-specific siRNAs ( Figure 5F ). When combined, GTPCH-and DHFR-specific knockdown resulted in markedly more eNOSderived superoxide (**P<0.05), and a diminished BH4:BH2 ratio ( †P<0.05) when compared to either GTPCH or DHFR knockdown alone ( Figure 5 ). These data suggest that either major reductions in de novo BH4 biosynthesis, or altered BH4:BH2 ratio through reduced BH4 recycling are each sufficient to induce eNOS uncoupling. Furthermore, the exacerbation of both BH4:BH2 ratio and eNOSdependent superoxide production by DHFR knockdown at low levels of total biopterin infers that DHFR activity is more significant at low, compared to high or saturating levels of BH4.
Quantitative relationships between GTPCH expression, DHFR and BH4 homeostasis in GCH cells
We investigated the effects of DHFR inhibition, using MTX, in cells expressing hemagglutininantigen (HA) tagged-human GTPCH under the control of a tetracycline responsive element (GCH cells) (7) . Titrating doxycycline concentration between 0.01 and 1 ng/ml to manipulate GTPCH expression, and therefore de novo BH4 synthesis, resulted in the expected concentration-dependent reduction in steadystate intracellular BH4 levels. However, coincubation with MTX significantly reduced BH4 levels, across the whole range of GTPCH expression, while markedly elevating intracellular BH2 levels (P<0.05; Figure 6 ). Importantly, the relative magnitude of the effect of DHFR inhibition by MTX was significantly greater at low absolute biopterin levels ( Figure  6 ). Intracellular BH4 levels were reduced by 25% at 0.01 ng/ml doxycycline (i.e. high GTCPH and high total biopterins) vs. 47% reduction at 1 ng/ml doxycycline (i.e. low GTPCH and low total biopterins).
DHFR protects against eNOS uncoupling
We reasoned that the potential importance of DHFR in BH4 recycling under low total bioterin conditions might be critical in eNOS uncoupling, where eNOS-dependent ROS production can itself lead to BH4 oxidation. To test this hypothesis, we compared the effects of DHFR inhibition by MTX in GCH cells vs. GCH cells stably expressing an eNOS-GFP fusion protein (GCH/eNOS cells), at different levels of GTPCH expression as determined by doxycycline.
We confirmed by Western blotting that eNOS protein was abundant in GCH/eNOS cells but not GCH cells, and that transgenic GTPCH protein was present equally in both GCH and GCH /eNOS cells, but was undetectable following incubation with doxycycline for 7 days. Importantly, neither eNOS nor DHFR protein levels were altered by doxycycline or MTX exposure ( Figure 7A ). Incubation of both GCH and GCH/eNOS cells with doxycycline, MTX or both in combination resulted in a marked suppression of intracellular BH4 levels (*P<0.05). However, BH4 levels in GCH/eNOS cells were significantly lower than those in GCH cells following doxycycline exposure, associated with increased accumulation of BH2 ( Figure 7B and C). BH2 accumulation in GCH/eNOS cells was significantly higher in the presence of both MTX and DOX, when compared to DOX alone ( Figure 7C ; †P<0.05). The BH4:BH2 ratio, a key determinant of eNOS coupling was not altered in GCH cells following doxycycline treatment in either the presence or absence of MTX. However, a striking doxycycline-induced decrease in the ratio of BH4:BH2 was observed in GCH/eNOS cells, that was further exacerbated in the presence of MTX ( Figure  7D ). Similarly, eNOS:BH4 ratio, determined by fluorescent quantification of eNOS-GFP fusion protein in cell lyastes, was reduced by MTX (21.2 ± 4.6 to 13.0 ± 0.9) and by doxycycline (21.2 ± 4.6 to 0.9 ± 0.6) ( Table 1) . Both GCH and GCH/eNOS cells showed a MTX-induced accumulation of 2-hydroxyethidium, indicative of superoxide production ( Figure 8A and B) . However, superoxide production was only inhibitable with L-NAME, indicating superoxide production from uncoupled eNOS, in GCH/eNOS cells but not in GCH cells ( Figure  8C and D) . Taken together, these data support evidence from our experiments using RNA interference and suggest that DHFR is required to maintain eNOS coupling, in particular under conditions of low biopterin synthesis.
DISCUSSION
In this study we used both pharmacologic inhibition, and genetic manipulation to determine the role of DHFR in the regulation of BH4 levels in sEnd.1 endothelial cells, and in cell lines which express tetracycline-regulatable human GTCPH and an eNOS-GFP fusion construct, described previously (7). We reveal a key role for DHFR, and the recycling pathway of BH4 biosynthesis in the maintenance of intracellular BH4 homeostasis. We also show that DHFR protein expression is an important factor in the preservation of eNOS coupling and subsequently the production of nitric oxide and superoxide. The major findings of this study are as follows: First, we demonstrate that endothelial cells contain substantial amounts of DHFR protein and that further augmentation of DHFR does not affect NO, BH4 or superoxide biosynthesis. Second, inhibition of DHFR activity or reduction of DHFR protein levels (following exposure to MTX or DHFR-specific siRNA, respectively), results in BH4 oxidation to BH2, decreased production of NO and elevation of eNOS-derived superoxide, indicative of eNOS uncoupling. Third, that this initiation of eNOS uncoupling by inhibition/knockdown of DHFR protein activity is exacerbated in conditions where BH4 is low or limiting. Finally, we reveal that DHFR is protective against eNOS uncoupling, demonstrated when cells expressing abundant eNOS, are exposed to MTX, particularly at low levels of GTPCH expression, where reduced cellular BH4 increases the susceptibility to eNOS uncoupling, including "self-induced" eNOS uncoupling resulting from eNOSdependent BH4 oxidation. Taken together, our findings provide clear mechanistic evidence to support a critical role of the recycling pathway in the regulation of cellular BH4 homeostasis and eNOS coupling, even in the absence of vascular disease or exogenous oxidative stress.
Biosynthesis of BH4, initially characterized by its cofactor role in reactions catalysed by the aromatic amino acid hydroxylases, proceeds via the de novo pathway involving enzymes GTPCH, PTPS and SR (Figure 1)(18) . As the rate-limiting enzyme in BH4 synthesis, GTPCH regulation takes place at the transcriptional and post-translational levels, with activity and mRNA shown to be induced by mediators such as IFN-γ, TNF-α and LPS (19) (20) (21) . Indeed, steady state BH4 levels in cells and tissues have previously been shown to directly correlate with GTPCH mRNA levels. BH4, also a cofactor for NOS enzymes, is required for efficient oxidation of arginine and ultimately NO production. When BH4 availability is limiting, eNOS generates superoxide rather than NO, BH4 becomes oxidized to catalytically incompetent BH2, and a futile feed-forward cascade of BH4 destruction proceeds.
A BH2-reductase activity of DHFR was first observed in cell and tissue extracts: In a Chinese hamster ovary cell mutant lacking dihydrofolate reductase (DUKX-BII), endogenous formation of BH4 proceeds normally but, unlike the parent cells, that express DHFR, extracts do not convert sepiapterin or BH2 to BH4 (22) . These studies implicate the biopterin recycling pathway in the regulation of steady state BH4 levels. Our data suggests that this BH2-reductase activity of DHFR is crucial in determining cellular BH4 homeostasis, NO bioavailability and ultimately eNOS coupling. The marked accumulation of BH2, resulting from DHFR inhibition or knockdown, would compete with BH4 for eNOS binding, diminish NO production and elevate the synthesis of eNOS-derived superoxide. The lack of any change in total biopterin levels by DHFR inhibition or knockdown suggests that de novo synthesis of BH4 is unaffected. In contrast, GTPCH-specific siRNA diminished total intracellular biopterins by over 90% with no change in BH4:BH2 ratio. Although elevated production of eNOS-derived superoxide was observed in GTPCH-siRNA treated cells, previous data from our group has shown this to be due to the reduced BH4:eNOS stoichiometry, not a decrease in BH4:BH2 ratio (7). Combined knockdown of GTPCH and DHFR in sEnd.1 endothelial cells provides insight into a differing significance or importance of DHFR activity at high vs. low levels of total biopterin. When combined, DHFR-and GTPCH-specific knockdown resulted in significantly elevated eNOS-derived superoxide when compared to either treatment alone, possibly as a result of the increased accumulation of BH2 and diminished ratio of BH4:BH2.
To complement this finding we specifically tested the role of DHFR in eNOS coupling using cell lines with tetracycline-regulated expression of human GTPCH and an eNOS-GFP fusion protein (GCH and GCH/eNOS cells) (7) , that are characterized by a doxycycline-induced decrease in BH4:BH2 ratio in the presence, but not absence of eNOS. Herein, we demonstrate that this eNOS uncoupling is further exacerbated in the absence of DHFR activity, as evidenced by MTX-induced superoxide production in GCH/eNOS cells that is inhibitable by L-NAME. These data would suggest that GTPCH protein is the principal enzyme determining overall production of BH4, while DHFR maintains the BH4 pool in a reduced state, limiting the accumulation of oxidized biopterins. Since BH4 recycling by DHFR will simultaneously increase BH4 and reduce BH2, the impact of DHFR on BH4:BH2 ratio is substantial, conferring DHFR as having a potentially critical role in regulating eNOS coupling and ultimately eNOS function. Indeed, DHFR has recently been shown to have other regulatory effects on eNOS that may complement our observations. Michel and colleagues have shown that perturbation of BH4 metabolism differentially affects BH4 levels and eNOS phosphorylation sites. Knockdown of DHFR by siRNA inhibits VEGF-induced dephosphorylation of eNOS at Ser-116, an effect that is completely recovered by addition of exogenous BH4 (8) . DHFR would have important consequences for the development of endothelial dysfunction in vascular disease states; our work supports and adds to the important observations of Chapulsky and Cai, who reported that oxidative stimuli such as angiotensin II can reduce DHFR activity in endothelial cells, leading to eNOS uncoupling (2) .
Experiments using endothelium-targeted eNOS over-expressing mice have indicated that increased eNOS protein alone is not sufficient to maintain endothelial function in vascular disease. Kawashima and colleagues reported that over-expression of eNOS in an ApoE-KO background paradoxically resulted in increased vascular superoxide production, at least in part from uncoupled eNOS, which was prevented when supplementary BH4 was administered (23) , or when these mice were further crossed with endothelium-targeted GTPCH transgenic mice (24) . Although these data describe BH4 deficiency as a result of oxidation to BH2, evidence from this study and the observation that DHFR levels are diminished in mouse models of diabetes may suggest that insufficient recycling of BH2 to BH4 by DHFR is at least in part responsible, allowing the accumulation of BH2 and eNOS uncoupling to occur. Indeed, DHFR protein levels are significantly decreased in streptozotocin-induced diabetic mice and diabetes-induced impairment of myocyte function is exacerbated following treatment of the mice with MTX (25) . Furthermore, due to the lack of DHFR activity, adult cardiac myocytes have limited capacity to synthesize BH4 after cytokine stimulation following treatment of rat cardiac allograft recipients with sepiapterin (26) . An insufficiency of DHFR may also explain results obtained in hypercholesterolemic rabbits where prolonged exposure to sepiapterin impaired vasorelaxation, despite repletion of endogenous BH4 (27) .
Pharmacological supplementation of BH4 improves endothelium-dependent relaxations and augments NO-mediated effects on forearm blood flow in smokers and those with diabetes and elevated cholesterol (28) (29) (30) . However, inefficient utilization of the administered BH4 remains problematic (31, 32) . Recent studies in cells and in vivo suggest that DHFR is required for biopterin transport. BH4 accumulation in various tissues after supplementation with BH4, BH2 or sepiapterin can be inhibited by MTX, indeed after MTX treatment the increase in tissue biopterin was almost exclusively BH2 (33) . It was concluded that the elevation in BH4 by supplementation was mainly through a "salvage pathway" that included BH2 as the key intermediate in the production of BH4 through the action of dihydrofolate reductase. It is therefore likely that DHFR expression is critical to cells which do not contain the apparatus required for efficient synthesis of BH4. BH2 may be transported from cells such as endothelial cells, reduced back to BH4 by DHFR, and made available for the synthesis of NO or catecholamines.
NO homeostasis is tightly regulated and sufficient NO production by the endothelium is required to maintain normal endothelial function. Due to the essential functions of DHFR and tetrahydrofolates, the DHFR inhibitor, MTX has become the most widely used single therapeutic agent for cancer (1, 2) and the preferred therapeutic for rheumatoid arthritis (34, 35) . Although little is known about the potential effects of MTX on the vasculature, one adverse effect of MTX treatment and DHFR inhibition may be due to the role of DHFR in regulating nitric oxide availability and biopterin metabolism. Perhaps patients receiving MTX therapy should be administered BH4 to supplement possibly deficient levels and maintain vascular function. Accordingly, therapeutic strategies to augment endothelial BH4 levels and/or suppress intracellular BH2 accumulation are rational approaches to maintain eNOS coupling in vascular conditions. with DHFR-and GCH-specific, control GAPDH or scrambled nonspecific siRNA, as described in Experimental Procedures. (A) DHFR and GTPCH-specific siRNAs alone, or in combination knocked down protein levels by over 90%. Importantly GTPCH and GAPDH knockdown, as well as scrambled control siRNAs did not have any effect on DHFR protein levels. (B) Intracellular BH4 levels were decreased 40% and 95% by DHFR-and GTPCH-specific siRNAs, respectively (*P<0.05). (C) A 2-fold increase in BH2 levels was induced by DHFR-specific siRNA (*P<0.05), and a 95% reduction was observed following exposure of sEnd.1 cells to GTPCH-specific siRNA (**P<0.001). Combined knockdown of GTPCH and DHFR resulted in a 4-fold increase in BH2 when compared to cells exposed to GTPCH-specific siRNA alone ( †P<0.05). (D) Total biopterins were unchanged by DHFR-specific siRNA and reduced by approximately 95% following exposure of sEnd.1 endothelial cells to GTPCHspecific siRNA, or when combined with DHFR-specific siRNA. (**P<0.001). (E) Intracellular BH4:BH2 ratio was markedly decreased by DHFR-, but not GTPCH-specific siRNA exposure (*P<0.05). Importantly, BH4:BH2 ratio was further decreased when endothelial cells were exposed to both GTPCHand DHFR-specific siRNAs combined ( †P<0.05). (F) eNOS-dependent superoxide production was induced by GTPCH-(*P<0.05) and DHFR-specific (*P<0.05) siRNA, however when combined led to a significantly increased production vs either GTPCH-or DHFR-siRNAs alone (**P<0.001). (G) A23187-induced conversion of arginine to citrulline cells was diminished by DHFR-(*P<0.05) and GTPCHspecific siRNAs (**P<0.001). Blots shown are representative of three separate experiments. All biopterin and arginine to citrulline measurements were unaffected by GAPDH knockdown or scrambled control siRNAs (n=6). Supplementary figure 1. MTX-induced changes in superoxide dismutase enzymes in sEnd.1, GCH and GCH/eNOS cells were analysed by western blotting using CuZn-, Mn-and EC SOD-specific antibodies. No significant changes in SOD were detected (n=3).
Supplementary figure 2. MTX significantly reduced cellular antioxidant capacity of sEnd.1, GCH and GCH/eNOS cells. Cellular antioxidant status was assessed using the Cayman Chemicals antioxidant kit as described in the Experimental Procedures section. MTX treatment (1 µM, 16 hours) was sufficient to induce a striking decrease in cellular antioxidant capacity of sEnd.1, GCH and GCH/eNOS cells respectively (*P<0.05, n=6).
Supplementary figure 3. Genetic Knockdown of DHFR and in GCH/eNOS cells in the absence and presence of doxycycline. Following exposure to doxycycline (1 ng/ml), GCH/eNOS cells were transfected with DHFR-specific siRNA, as described in Experimental Procedures. (A) Exposure of GCH/eNOS cells to DHFR-specific siRNA in both the absence (high total biopterin) and presence (low total biopterin) of doxycycline resulted in no significant change in BH4 levels. (B) A 2-fold increase in BH2 was induced by DHFR knockdown at both high and low levels of total biopterin. (C) Consequently, intracellular BH4:BH2 ratio was markedly decreased by either DHFR-specific siRNA or doxycycline alone (3-fold, *P<0.05). Importantly, BH4:BH2 ratio was further decreased when cells were exposed to DHFR-specific siRNAs in the presence of doxycycline, at low levels of total biopterin ( †P<0.05, n=3). 
